Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 6.4 Million USD | -91.64% |
| 2023 | 76.53 Million USD | 6.77% |
| 2022 | 71.68 Million USD | -17.89% |
| 2021 | 87.3 Million USD | 36.41% |
| 2020 | 64 Million USD | 7.69% |
| 2019 | 59.43 Million USD | 4.94% |
| 2018 | 56.63 Million GBP | -7.62% |
| 2017 | 61.31 Million GBP | -45.2% |
| 2016 | 111.89 Million GBP | 88.05% |
| 2015 | 59.5 Million GBP | 42.34% |
| 2014 | 41.8 Million GBP | 15.15% |
| 2013 | 36.3 Million GBP | -33.03% |
| 2012 | 54.2 Million GBP | 20.98% |
| 2011 | 44.8 Million GBP | -4.68% |
| 2010 | 47 Million GBP | 42.42% |
| 2009 | 33 Million GBP | 25.95% |
| 2008 | 26.2 Million GBP | -7.75% |
| 2007 | 28.4 Million GBP | 41.29% |
| 2006 | 20.1 Million GBP | 127.12% |
| 2005 | 8.85 Million GBP | 1.19% |
| 2004 | 8.74 Million GBP | -14.15% |
| 2003 | 10.18 Million GBP | 35.9% |
| 2002 | 7.49 Million GBP | 17.42% |
| 2001 | 6.38 Million GBP | 13.29% |
| 2000 | 5.63 Million GBP | 61.14% |
| 1999 | 3.49 Million GBP | 16.8% |
| 1998 | 2.99 Million GBP | 55.61% |
| 1997 | 1.92 Million GBP | 132.65% |
| 1996 | 827 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 13.05 Million GBP | -60.15% |
| 2024 Q2 | 27.11 Million USD | 107.78% |
| 2024 FY | 8.09 Million USD | -89.43% |
| 2024 Q4 | -18.83 Million USD | 0.0% |
| 2023 Q2 | 17.77 Million USD | 4.58% |
| 2023 Q1 | 17 Million GBP | 22.74% |
| 2023 Q3 | 13.35 Million GBP | -24.91% |
| 2023 Q4 | 32.74 Million USD | 145.3% |
| 2023 FY | 76.53 Million USD | 6.77% |
| 2022 Q1 | 14.45 Million GBP | 11.58% |
| 2022 FY | 71.68 Million USD | -17.89% |
| 2022 Q3 | 13.85 Million GBP | -4.15% |
| 2022 Q2 | 14.45 Million USD | 0.0% |
| 2022 Q4 | 13.85 Million USD | 0.0% |
| 2021 FY | 87.3 Million USD | 36.41% |
| 2021 Q2 | 17.8 Million USD | 0.0% |
| 2021 Q1 | 17.8 Million GBP | 96.69% |
| 2021 Q4 | 12.95 Million USD | 0.0% |
| 2021 Q3 | 12.95 Million GBP | -27.25% |
| 2020 Q2 | 13.65 Million USD | 0.0% |
| 2020 Q4 | 9.05 Million USD | 0.0% |
| 2020 FY | 64 Million USD | 7.69% |
| 2020 Q1 | 13.65 Million GBP | -62.29% |
| 2020 Q3 | 9.05 Million GBP | -33.7% |
| 2019 Q1 | -14.05 Million GBP | -140.72% |
| 2019 Q3 | 36.2 Million GBP | 357.65% |
| 2019 FY | 59.43 Million USD | 4.94% |
| 2019 Q4 | 36.2 Million USD | 0.0% |
| 2019 Q2 | -14.05 Million GBP | 0.0% |
| 2018 Q1 | -13.6 Million GBP | -144.44% |
| 2018 Q2 | -13.6 Million GBP | 0.0% |
| 2018 FY | 56.63 Million GBP | -7.62% |
| 2018 Q3 | 34.5 Million GBP | 353.68% |
| 2018 Q4 | 34.5 Million GBP | 0.0% |
| 2017 Q4 | 30.6 Million GBP | 0.0% |
| 2017 FY | 61.31 Million GBP | -45.2% |
| 2017 Q1 | -10.3 Million GBP | -212.57% |
| 2017 Q2 | -10.3 Million GBP | 0.0% |
| 2017 Q3 | 30.6 Million GBP | 397.09% |
| 2016 FY | 111.89 Million GBP | 88.05% |
| 2016 Q4 | 9.15 Million GBP | 0.0% |
| 2016 Q3 | 9.15 Million GBP | -3.17% |
| 2016 Q2 | 9.45 Million GBP | 0.0% |
| 2016 Q1 | 9.45 Million GBP | 126.85% |
| 2015 FY | 59.5 Million GBP | 42.34% |
| 2015 Q3 | -35.2 Million GBP | -461.03% |
| 2015 Q1 | 9.75 Million GBP | 125.9% |
| 2015 Q2 | 9.75 Million GBP | 0.0% |
| 2015 Q4 | -35.2 Million GBP | 0.0% |
| 2014 Q4 | -37.65 Million GBP | 0.0% |
| 2014 FY | 41.8 Million GBP | 15.15% |
| 2014 Q3 | -37.65 Million GBP | -550.9% |
| 2014 Q2 | 8.35 Million GBP | 0.0% |
| 2014 Q1 | 8.35 Million GBP | -1.76% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | 36.3 Million GBP | -33.03% |
| 2013 Q4 | 8.5 Million GBP | 0.0% |
| 2013 Q3 | 8.5 Million GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | 54.2 Million GBP | 20.98% |
| 2011 FY | 44.8 Million GBP | -4.68% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | 47 Million GBP | 42.42% |
| 2010 Q2 | - GBP | 0.0% |
| 2009 FY | 33 Million GBP | 25.95% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 26.2 Million GBP | -7.75% |
| 2007 Q2 | - GBP | 0.0% |
| 2007 FY | 28.4 Million GBP | 41.29% |
| 2006 FY | 20.1 Million GBP | 127.12% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | 8.85 Million GBP | 1.19% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2004 FY | 8.74 Million GBP | -14.15% |
| 2003 FY | 10.18 Million GBP | 35.9% |
| 2002 FY | 7.49 Million GBP | 17.42% |
| 2001 FY | 6.38 Million GBP | 13.29% |
| 2000 FY | 5.63 Million GBP | 61.14% |
| 1999 FY | 3.49 Million GBP | 16.8% |
| 1998 FY | 2.99 Million GBP | 55.61% |
| 1997 FY | 1.92 Million GBP | 132.65% |
| 1996 FY | 827 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 579.246% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 226.871% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 135.86% |
| Nascent Biotech, Inc. | -2.22 Million USD | 387.011% |
| Rebus Holdings, Inc. | -664 Thousand USD | 1063.855% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 92.181% |
| Qrons Inc. | -643.67 Thousand USD | 1094.288% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 1742.837% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 111.53% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1640.391% |
| Skye Bioscience, Inc. | -13.67 Million USD | 146.812% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 108.915% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -30.219% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 2545.305% |
| SQZ Biotechnologies Company | -75.82 Million USD | 108.44% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 324.521% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 516.653% |
| Mesoblast Limited | -84.14 Million USD | 107.606% |
| Marizyme, Inc. | -34.08 Million USD | 118.776% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 34.308% |
| Pharming Group N.V. | -4.87 Million USD | 231.16% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 422.178% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 787.152% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 176.647% |
| ContraFect Corporation | -56.88 Million USD | 111.25% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 240.513% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 556.494% |
| IMV Inc. | -38.67 Million USD | 116.55% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 332.656% |
| MultiCell Technologies, Inc. | -722.81 USD | 885533.24% |
| ONE Bio Corp. | 13.68 Million USD | 53.222% |
| Accustem Sciences Inc. | -3.74 Million USD | 270.83% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 110.849% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 1424.882% |
| Q BioMed Inc. | -3.44 Million USD | 285.743% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -80.791% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 343.576% |
| Biomind Labs Inc. | -1 Million USD | 733.913% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 111.642% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 320.595% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 196.269% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 443.279% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 21467.521% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 140.328% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 431.158% |
| GB Sciences, Inc. | -1.42 Million USD | 550.543% |
| Alpha Cognition Inc. | -9.7 Million USD | 165.941% |
| HST Global, Inc. | -140.9 Thousand USD | 4642.003% |
| CSL Limited | 3.7 Billion USD | 99.827% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 668.936% |
| Halberd Corporation | -75.05 Thousand USD | 8627.648% |
| Enzolytics Inc. | -2.14 Million USD | 397.841% |
| Agentix Corp. | -1.37 Million USD | 566.555% |
| Resverlogix Corp. | -12.74 Million USD | 150.2% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 302.003% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 101.506% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 713.027% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 319.22% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 505.229% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 287.96% |
| AVAX Technologies, Inc. | 6.69 Million USD | 4.376% |
| Zenith Capital Corp. | -8.94 Million USD | 171.564% |
| Genscript Biotech Corporation | -415.79 Million USD | 101.539% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 36837.271% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 360.659% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 3831.571% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 419.241% |
| Kadimastem Ltd | -3.04 Million USD | 310.509% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 750.371% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 609.554% |
| BioStem Technologies, Inc. | -7.77 Million USD | 182.273% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 3626.462% |
| LadRx Corporation | -3.82 Million USD | 267.38% |
| Cell Source, Inc. | -4.32 Million USD | 247.965% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1031.654% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1031.654% |
| NovAccess Global Inc. | -2.46 Million USD | 359.45% |
| Affymax, Inc. | -15.04 Million USD | 142.536% |
| Itoco Inc. | -919.14 Thousand USD | 796.303% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 251.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 671.939% |
| Mobile Lads Corp. | -554.55 Thousand USD | 1254.089% |
| CytoDyn Inc. | -18.05 Million USD | 135.441% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 25527.096% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 3008.06% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 1233.299% |
| SYBLEU INC | -149.18 Thousand USD | 4390.119% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 452.361% |
| International Stem Cell Corporation | -663 Thousand USD | 1065.309% |
| Bioxytran, Inc. | -3.82 Million USD | 267.533% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 12258.055% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 31565.093% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 117.647% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 495.55% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 969.76% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 305.722% |
| Neutra Corp. | -229.48 Thousand USD | 2888.841% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 136.49% |
| PureTech Health plc | -146.19 Million USD | 104.378% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 129.78% |
| IXICO plc | -1.43 Million USD | 545.372% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 167.432% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 105.254% |
| CSL Limited | 3.81 Billion USD | 99.832% |
| Cellectis S.A. | -108.85 Million USD | 105.879% |